Lunit Forms Strategic Partnership with US Diagnostic Leader "Labcorp"

Expanding Joint Research and Development Across Multiple Cancer Types

On November 18, Lunit, a medical artificial intelligence (AI) company, announced that it has entered into a strategic partnership with Labcorp, a leading global provider of diagnostic and clinical trial services, to collaborate in the field of AI-based digital pathology.

The two companies formalized their partnership by presenting the results of their first joint research at the "2025 Society for Immunotherapy of Cancer (SITC)" and the "2025 Association for Molecular Pathology (AMP)" conferences held recently in the United States.

Labcorp is the world's top company in diagnostic and clinical trial services, headquartered in North Carolina, USA. With approximately 70,000 employees across more than 100 countries, Labcorp conducts over 700 million diagnostic tests annually. The company provides clinical trial and analytical services throughout the development process of new drugs and therapies approved by the U.S. Food and Drug Administration (FDA). This collaboration aims to combine Labcorp's extensive clinical and pathological expertise with Lunit's AI algorithms to dramatically improve tumor microenvironment analysis and accelerate the discovery of biomarkers that predict immunotherapy response.

The first outcome of the collaboration is a study that identified the characteristics of the tumor microenvironment in non-small cell lung cancer (NSCLC) patients according to MET mutation types. At SITC 2025, the joint research team from Lunit and Labcorp analyzed pathology slides from a total of 371 patients-including those with MET exon 14 skipping, those with MET amplification, and those without MET mutations-using Lunit SCOPE IO, and classified the immunotherapy response according to each mutation type.

Furthermore, at AMP 2025, analysis using Lunit SCOPE IO confirmed that the tumor microenvironment of non-small cell lung cancer patients shows distinct differences depending on the MET mutation type, and that the response to immunotherapy also varies accordingly.

Through this research, the two companies confirmed the potential of AI-based digital pathology technology to contribute to immunotherapy-related studies and plan to expand their collaboration to large-scale research using real-world data (RWD) and to other cancer types in the future.

Seo Bumseok, CEO of Lunit, stated, "Being recognized by a global leader like Labcorp will serve as an important foundation for Lunit's AI technology to be widely utilized in real-world clinical oncology settings. The integration of AI and digital pathology will be a key driver in translating insights gained during the research phase into actual treatment-related decision-making."

Shakti Ramkissoon, Chief Medical Officer of Oncology at Labcorp, said, "We look forward to deriving meaningful clinical value from vast and complex pathology data together with Lunit. This research has demonstrated that AI-based digital pathology technology can accurately identify tumor characteristics and help design personalized treatment strategies."

This content was produced with the assistance of AI translation services.